 |
80 Diseases |  |
208 Trials |
|
208 Trials |  |
5617 News |  |
| «12...2425262728293031323334...7172» |
- || Trial completion date: CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - Mar 8, 2022
P2, N=790, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2023 --> Jun 2024
- ||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Clinical: Although frontline SOC for metastatic HER2+ breast cancer remains trastuzumab, pertuzumab, & a taxane, the second-line has had a paradigm shift w/ the incorporation of fam-trastuzumab deruxtecan-nxki as a standard option @RutaRaoMD @RushMedical #bcsm https://t.co/8eSiYEFCvi (Twitter) - Mar 8, 2022
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche, Verzenio (abemaciclib) / Eli Lilly
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases: ACCRU-BR-1801: T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 7, 2022
P2, N=0, Withdrawn, Sponsor: Academic and Community Cancer Research United
Trial completion date: Jun 2023 --> Jun 2024 N=126 --> 0 | Trial completion date: May 2027 --> Feb 2022 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Feb 2022
- || Trial primary completion date, Combination therapy, Metastases: The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer (clinicaltrials.gov) - Mar 4, 2022
P2, N=100, Recruiting, Sponsor: Adrienne G. Waks
N=126 --> 0 | Trial completion date: May 2027 --> Feb 2022 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Feb 2022 Trial primary completion date: Jan 2022 --> Jul 2022
- | Herceptin (trastuzumab) / Roche
Journal: Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. (Pubmed Central) - Mar 1, 2022
Thus, similar to oncogenic mutations, therapeutic agents exploit the intrinsic dynamics of the HER2-HER3 heterodimer. The unique features of a singly liganded HER2-HER3 heterodimer underscore the allosteric sensing of ligand occupancy by the dimerization interface and explain why extracellular domains of HER2 do not homo-associate via a canonical active dimer interface.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Preclinical, Journal: Inflammatory Related Reactions in Humans and in Canine Breast Cancers, A Spontaneous Animal Model of Disease. (Pubmed Central) - Mar 1, 2022
These reactions were less frequently reported for pertuzumab i.v. Case reports of platelet and neutrophil count decrease were not associated with disease progression with a better outcome in humans as in canine breast cancer. Therefore, infiltrating CD68-macrophages are associated with G3, while infiltrating CD20 and elevated serum lymphocytes in parallel with reduced platelet and neutrophil count play a favorable role in human and canine breast cancer.
- | Herceptin (trastuzumab) / Roche
Journal: More Than Meets the Kappa for Antibody Superantigen Protein L (PpL). (Pubmed Central) - Mar 1, 2022
Through this holistic and systemic analysis of IgG1 variants with various antibody regions modified, comparisons revealed novel PpL-antibody interactions influenced by other non-canonical antibody known light-chain framework regions, whereas SpA and SpG showed relatively consistent interactions. These findings have implications on PpL-based affinity antibody purification and design that can guide the engineering and understanding of PpL-based microbiota-immune effects.
- | Herceptin (trastuzumab) / Roche
Journal: FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer. (Pubmed Central) - Feb 27, 2022
In the subset of patients treated with TZ/PZ combined, the pCR rate was significantly lower among those showing FGFR1 amplification (p = 0.021). Although based on a small sample size, our findings suggest that patients with FGFR1 amplification might benefit less from anti-HER2 antibody therapy.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report. (Pubmed Central) - Feb 26, 2022
OTC for fertility preservation in patients with PrBC does not delay breast surgery, radiotherapy or chemotherapy, which is essential for effective treatment of breast cancer. We assess this method as a promising fertility preservation method which was used here for the first time worldwide in a patient who developed breast cancer during pregnancy.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. (Pubmed Central) - Feb 26, 2022
The optimal cutoff of AR for predicting pCR was 85%. (4) AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: Preference of trastuzumab emtansine as a second or third line treatment in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer refractory to trastuzumab and pertuzumab. (Pubmed Central) - Feb 25, 2022
(4) AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. No abstract available
- Herceptin (trastuzumab) / Roche
Administering Subcutaneous (SubQ) Hyaluronidase Injections with a Medication Extension Set (ExSet) (Anaheim Convention Center - Learning Hall: Poster Pavilion) - Feb 25, 2022 - Abstract #ONS2022ONS_252;
Innovation: Our working group has outlined a safe way to administer hyaluronidase containing medications using an ExSet, which has not been previously described with similar anticancer medications. Injection technique with the ExSet improves self-reported body mechanics to potentially prevent work related repetitive stress injury.
- | Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2/3 trial: NRG-GY026: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (clinicaltrials.gov) - Feb 25, 2022
P2/3, N=326, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | New P1/2 trial, Metastases: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) - Feb 25, 2022
P1/2, N=48, Not yet recruiting, Sponsor: Georgetown University
- | Herceptin (trastuzumab) / Roche
Journal: Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. (Pubmed Central) - Feb 24, 2022
This is likely due to considerable conformational flexibilities across the span of these receptor molecules and substantial undulations in the plane of the plasma membrane, none of which had been foreseen as impediments to targeting strategies. The massive overexpression of HER2 functionally and physically uncouples intracellular signaling from extracellular constraints.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial, Real-world evidence, Real-world: Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer (clinicaltrials.gov) - Feb 23, 2022
P2, N=60, Not yet recruiting, Sponsor: Fujian Medical University Union Hospital
- ||| Herceptin (trastuzumab) / Roche, Imfinzi (durvalumab) / AstraZeneca, Perjeta (pertuzumab) / Roche
Clinical: First line setting? I don’t think we have good evidence for Chemo + HER2, would most probably go for GEM/CIS Durvalumab and then follow up with Trastuzumab/Pertuzumab. Opinions? (Twitter) - Feb 23, 2022
- || Kadcyla (ado-trastuzumab emtansine) / Roche
Clinical, Journal: Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer. (Pubmed Central) - Feb 22, 2022
The massive overexpression of HER2 functionally and physically uncouples intracellular signaling from extracellular constraints. Unlike with conventional chemotherapy, the line of treatment in which T-DM1 is administered does not influence PFS in our cohort of patients with advanced HER2-positive breast cancer.
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
P3 data, Journal: Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. (Pubmed Central) - Feb 22, 2022
P3
Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
- | Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
Preclinical, Journal: Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. (Pubmed Central) - Feb 22, 2022
In addition, dual HER2 blockade using anti-HER2Ab LM008 NSCs and the tyrosine kinase inhibitor tucatinib significantly improved the survival of mice in a clinically relevant model of multiple HER2+ BCBM. These findings provide compelling evidence for the use of HER2Ab-secreting LM008 NSCs in combination with tucatinib as a promising therapeutic regimen for patients with HER2+ BCBM.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Feb 21, 2022
P1b, N=198, Active, not recruiting, Sponsor: Eli Lilly and Company
These findings provide compelling evidence for the use of HER2Ab-secreting LM008 NSCs in combination with tucatinib as a promising therapeutic regimen for patients with HER2+ BCBM. Trial completion date: Oct 2022 --> Oct 2023
- || TAEK-VAC-HerBy vaccine / Bavarian Nordic
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - Feb 21, 2022
P1, N=55, Recruiting, Sponsor: Bavarian Nordic
Trial completion date: Oct 2022 --> Oct 2023 Phase classification: P1/2 --> P1 | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2024
- |||||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (clinicaltrials.gov) - Feb 20, 2022
P3, N=372, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase classification: P1/2 --> P1 | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2024 Not yet recruiting --> Recruiting
- || MEDI4276 / AstraZeneca
Clinical, P1 data, Journal: First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2+ Advanced Breast or Gastric Cancer. (Pubmed Central) - Feb 19, 2022
In the as-treated population, there was 1 complete response (0.5 mg/kg; BC), and 2 partial responses (0.6 and 0.75 mg/kg; BC)-all had prior trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). MEDI4276 has demonstrable clinical activity but displays intolerable toxicity at doses >0.3 mg/kg.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
Biomarker, Journal: Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. (Pubmed Central) - Feb 19, 2022
MEDI4276 has demonstrable clinical activity but displays intolerable toxicity at doses >0.3 mg/kg. The identification of trastuzumab response biomarkers may be used to select patients particularly sensitive to facilitate the use of trastuzumab-based therapies and refine follow-up guidelines in patients with HER2+ tumors.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Observational data, Journal, Real-world evidence: PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. (Pubmed Central) - Feb 19, 2022
Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Retrospective data, Review, Journal: Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Feb 16, 2022
The T-DM1PC, T-DM1, and PTC_T-DM1P regimens had the optimal balance between efficacy and safety, while DFS was highest for the PTC regimen. However, these results were based on a small number of studies, and additional RCTs assessing the efficacy of regimens with T-DM1 are still needed to confirm these findings.
- | Herceptin (trastuzumab) / Roche
Journal: Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. (Pubmed Central) - Feb 16, 2022
Treatment significantly altered the absolute frequencies of individual complexes in SKBr3 and/or MDA-MB-361 cells, but in the presence of neuregulin-1, the overall distribution was not markedly altered, with HER2-HER3 and HER2-HER4 remaining predominant. Together, these findings suggest that markers of HER2 and HER3 expression are not always indicative of dimerization, and that pertuzumab may be less effective at reducing HER2-HER3 dimerization in the context of excess neuregulin.
- | Herceptin (trastuzumab) / Roche, hersintuzumab / Tehran University of Medical Sciences
Preclinical, Journal, Combination therapy: Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models. (Pubmed Central) - Feb 15, 2022
Similar results were obtained in the gastric (NCI-N87) and ovarian (SKOV-3) tumor xenograft models. Hersintuzumab in combination with trastuzumab induces synergic anti-tumor effects on HER2-overexpressing cells in vitro and in vivo and is potentially a therapeutic tool for treatment of HER2-overexpressing cancers.
- | Perjeta (pertuzumab) / Roche
Preclinical, Journal: Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [Tc]-(I)-Tricarbonyl Complex. (Pubmed Central) - Feb 15, 2022
MicroSPECT/CT with [Tc]His-pertuzumab Fab imaged tumors in NOD/SCID mice that exhibited intermediate or high HER2 expression, but not tumors with low HER2. [Tc]His-pertuzumab Fab is promising for SPECT imaging of tumor HER2 expression.
- | Tukysa (tucatinib) / Seagen
Retrospective data, Journal: Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. (Pubmed Central) - Feb 15, 2022
For OS, SUCRA ranked tucatinib plus trastuzumab with capecitabine as highest in both HR and FP analyses, followed by pertuzumab plus trastuzumab with capecitabine and T-DM1 monotherapy, with similar scores. Tucatinib plus trastuzumab with capecitabine, and T-DM1 monotherapy, consistently showed improved PFS and OS versus lapatinib/trastuzumab plus capecitabine and non-targeted treatments.
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, docetaxel / Generic mfg.
Clinical: 🎯 IFCT-1703 R2D2 trial: Combination of trastuzumab, pertuzumab & docetaxel demonstrates efficacy in patients w/ advanced non-small-cell #LungCancer harboring #HER2 mutations ➡️ https://t.co/Tt8j0scaKT #PrecisionMedicine #JCO #LCSM #nsclc @JulienMazieres @BenjaminBesseMD (Twitter) - Feb 15, 2022
- || Trial primary completion date: CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - Feb 10, 2022
P2, N=790, Recruiting, Sponsor: Hoffmann-La Roche
Tucatinib plus trastuzumab with capecitabine, and T-DM1 monotherapy, consistently showed improved PFS and OS versus lapatinib/trastuzumab plus capecitabine and non-targeted treatments. Trial primary completion date: Jul 2022 --> Feb 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-? Status in Patients With Metastatic Breast Cancer HER2 + and ER? Neg Treated With Trastuzumab + Pertuzumab + Taxane. (clinicaltrials.gov) - Feb 10, 2022
P=N/A, N=4, Terminated, Sponsor: Institut Claudius Regaud
Trial primary completion date: Jul 2022 --> Feb 2023 N=33 --> 4 | Trial completion date: Dec 2022 --> Jul 2021 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jun 2021; Slow recruitment rate
- || Biomarker, Clinical, Journal: The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis - A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up. (Pubmed Central) - Feb 9, 2022
In addition to the trastuzumab-induced ILD case, a prospective cohort in our facility also confirmed the usefulness of MPO-DNA in monitoring vasculitis activity. We postulated that upfront testing with biomarkers of vasculitis during HER2 targeted treatment with high ILD incidence may be beneficial in the future.
- || Perjeta (pertuzumab) / Roche
Clinical, Journal: Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. (Pubmed Central) - Feb 8, 2022
We postulated that upfront testing with biomarkers of vasculitis during HER2 targeted treatment with high ILD incidence may be beneficial in the future. In our cohort, prior exposure to pertuzumab did not significantly impact T-DM1's clinical efficacy or safety profile as second- or later-line therapy in patients with metastatic HER2-positive breast cancer.
- | Herceptin (trastuzumab) / Roche
Journal: Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. (Pubmed Central) - Feb 8, 2022
A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
- ||||| Clinical, NCCN guideline: 👆🏾This is for #colorectalcancer #CRCSM. The only options outside of clinical trials as per @NCCN guidelines 2nd line or beyond are: 1️⃣ Trastuzumab➕Lapatinib 2️⃣ Trastuzumab➕Pertuzumab 3️⃣ TDX-d I’d use the #2 approach, followed by #3 at progression. #HER2 🎯also Tucatinib ⛰ . (Twitter) - Feb 6, 2022
- || Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Do you reach for trastuzumab/pertuzumab before the chemo+pembro+trast regimen a la KN 811? (Twitter) - Feb 6, 2022
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Marginal corneal infiltration following treatment for metastatic breast cancer with triple chemotherapy of Trastuzumab, Pertuzumab & Docetaxel. (Pubmed Central) - Feb 4, 2022
We propose that trastuzumab, pertuzumab, and docetaxel suppress HER2 and Ki67 in the cornea and lacrimal gland. To the best of our knowledge, our report is the first to highlight the potential impact of this triple chemotherapy on the lacrimal gland and cornea and the first to highlight the proposed role of Ki67 suppression in damaging corneal integrity.
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Response to HER2-blockade in #colorectalcancer can be profound & very heartening. Tend to be LEFT-sided/Rectal. 👇🏾Just 2 doses of Trastuzumab/Pertuzumab. Chemo-free regimens. 3️⃣are now listed @NCCN for #CRCSM. 2nd line or beyond. #TumorBoardTuesday @PancPathologist @MPishvaian https://t.co/Jm5bvitOaw (Twitter) - Feb 4, 2022
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Active immunization with a multi-peptide B cell vaccine, targeting Trastuzumab and Pertuzumab binding sites, prevents the formation of Her-2/neu expressing lung metastases ([VIRTUAL]) - Feb 3, 2022 - Abstract #ESMOTAT2022ESMO_TAT_116;
Moreover, our suggest a combination therapy involving an anti-PD-L1 immune checkpoint inhibitor or potentially active immunization with a mimotope from PD-L1 to result in the remission of the metastases. Such a combination therapy to alternately target Her-2/neu and PD-L1 could be adapted to the stage and progression phase of the disease.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: HER2Pro 1B - Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (EUDRACT) - Feb 3, 2022
P1, N=12, Not yet recruiting, Sponsor: University of Queensland
- || Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal, Combination therapy: Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). (Pubmed Central) - Feb 1, 2022
Hence, we have started a randomized phase III study comparing eribulin and a taxane in combination with pertuzumab and trastuzumab for the treatment of HER2-positive AMBC. Trial registration ID: UMIN-CTR: UMIN000012232.
- || Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Clinical, Journal, Combination therapy: Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases. (Pubmed Central) - Feb 1, 2022
Trial registration ID: UMIN-CTR: UMIN000012232. No abstract available
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data. (Pubmed Central) - Feb 1, 2022
No abstract available Four cycles of pertuzumab, trastuzumab and taxane after neoadjuvant anthracycline for locally advanced HER2 breast cancer are associated with increased pCR in patients with grade 3 tumors and high cerbB2 expression.
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, docetaxel / Generic mfg.
Combination therapy: News: Combination therapy with pertuzumab, trastuzumab & docetaxel may be an option for advanced #NSCLC harboring HER2 exon 20 alterations, suggest @IFCTlung R2D2 trial results by @JulienMazieres @C_Ricordel @BenjaminBesseMD & colleagues in @JCO_ASCO https://t.co/lSrFgvtA9m (Twitter) - Jan 31, 2022
- ||| Herceptin (trastuzumab) / Roche
Clinical, P3 data, Journal: Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. (Pubmed Central) - Jan 29, 2022
P3
This supports the concept of an additional effect of NACT beyond pCR in patients with HR+/HER2- BC. CLINICALTRIALS.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
السلام عليكم دكتور هل دواءPertuzumab ,Herceptinيعمل على ارتفاع Anti-TPO (Twitter) - Jan 29, 2022
- ||| Perjeta (pertuzumab) / Roche
Pertuzumab has shown the OS in LN+ dz (& LN- dz might not have stats power), but AI+ OvS has this real concerning disconnect betw DFS but no OS despite f/u (why known cardiovascular risks -> CV or other collateral deaths explaing this disconnect should be a real concern for us). (Twitter) - Jan 29, 2022